Magnitude of Peroxisome Proliferator-Activated Receptor-γ Activation is Associated With Important and Seemingly Opposite Biological Responses in Breast Cancer Cells

• Published in: Journal of investigative medicine Vol. 49; no. 5; pp. 413 - 420
• Main Authors: Clay, Carl E., Namen, Andrew M., Atsumi, Gen-ichi, Trimboli, Anthony J., Fonteh, Alfred N., High, Kevin P., Chilton, Floyd H.
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.09.2001; SLACK INCORPORATED
• Subjects: Apoptosis - drug effects; Breast Neoplasms - pathology; Cell Cycle - drug effects; Cell Differentiation - drug effects; Cell Division - drug effects; Chromans - pharmacology; Female; Humans; Prostaglandin D2 - analogs & derivatives; Prostaglandin D2 - pharmacology; Receptors, Cytoplasmic and Nuclear - physiology; Thiazoles - pharmacology; Thiazolidinediones; Transcription Factors - physiology; Transcriptional Activation - drug effects; Tumor Cells, Cultured; breast cancer; apoptosis; differentiation; cell cycle arrest; PPARγ
• ISSN: 1081-5589; 1708-8267
• DOI: 10.2310/6650.2001.33786

BackgroundThe nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) has become a potential target for the prevention and treatment of breast cancer. However, recent in vitro and in vivo studies have raised the question of whether activation of PPARγ leads to the promotion or reduction of tumor formation. Studies using several cancer cell lines, animal models, and a variety of PPARγ agonists have shown discordant results, including changes in cellular proliferation, differentiation, and apoptosis of cancer cells and tumors.MethodsWe studied the effects of low-, moderate-, and high-dose treatment of the PPARγ ligands 15-deoxy-Δ12,14 prostaglandin J2 (15dPGJ2) and troglitazone (TGZ) on parameters of cell growth, differentiation, and apoptosis in the epithelial breast cancer cell line MDA-MB-231.ResultsThe biologic effects of these compounds depend largely on ligand concentration and the degree of PPARγ activation. For example, low concentrations of 15dPGJ2 (<2.5 μM) and TGZ (<5 μM) increased cellular proliferation, but concentrations of 15dPGJ2 >10 μM and of TGZ at 100 μM blocked cell growth. TGZ (100 μM) slowed cell cycle progression, and 15dPGJ2 (10 μM) caused an S-phase arrest in the cell cycle and induced morphological characteristics consistent with apoptosis. Expression of CD36, a marker of differentiation in these cells, was induced by 2.5 μM 15dPGJ2 or 5 to 100 μM TGZ. However, higher concentrations of 15dPGJ2 did not alter CD36 expression. Transcriptional activation studies demonstrated that 15dPGJ2 is a more potent PPARγ ligand than TGZ. Regardless of the ligand used, though, low transcriptional activation correlated with an increased cellular proliferation, whereas higher levels of activation correlated with cell cycle arrest and apoptosis.ConclusionsPPARγ activation induces several important and seemingly opposite changes in neoplastic cells, depending on the magnitude of PPARγ activation. These data may explain, at least in part, some of the discordant results previously reported.